PAVM PAVmed Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1624326 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY410.3%
TTM net income YoY-693.3%
TTM EPS YoY—
Revenue 3-yr CAGR-54.7%
Net income 3-yr CAGR—
Margins
Gross margin-212.2%
Operating margin-19,315.5%
Net margin-12,406.8%
FCF margin-3,024.3%
EBITDA margin-19,264.2%
Returns
ROE-61.2%
ROA-50.1%
ROIC (approx.)-84.8%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets71.2%
Debt / equity0.00x
Current ratio0.41x
Interest coverage-5,717.40x
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-38.1%
Payout ratio—
Capex / revenue38.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $41,000 | $33,000 | $22,000 | $52,000 | $5,000 | $6,000 | $8,000 | $10,000 |
| Cost of revenue | $158,000 | $122,000 | $97,000 | $85,000 | $55,000 | $41,000 | $36,000 | $48,000 |
| Gross profit | -$117,000 | -$89,000 | -$75,000 | -$33,000 | -$50,000 | -$35,000 | -$28,000 | -$38,000 |
| R&D expense | $1.92M | $2.07M | $1.39M | $1.83M | $1.09M | $790,000 | $787,000 | $807,000 |
| SG&A expense | $4.48M | $4.65M | $6.36M | $4.69M | $3.50M | $3.67M | $4.38M | $4.19M |
| Operating income | -$6.73M | -$7.02M | -$8.04M | -$6.80M | -$4.84M | -$4.71M | -$5.45M | -$5.19M |
| Interest expense | $5,000 | $2,000 | $3,000 | -$5,000 | $8,000 | $4,000 | $4,000 | $7,000 |
| Pretax income | -$13.04M | -$6.60M | -$1.06M | -$2.76M | -$6.01M | -$12.32M | $18.62M | $1.14M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$11.65M | -$5.38M | -$60,000 | -$1.26M | -$5.38M | -$11.92M | $18.97M | $1.43M |
| EBITDA | -$6.71M | -$7.00M | -$8.02M | -$6.79M | -$4.82M | -$4.69M | -$5.40M | -$5.12M |
| EPS (basic) | -1.77 | -0.87 | -4.42 | — | -8.81 | -22.08 | 38.26 | — |
| EPS (diluted) | — | -0.87 | -4.42 | — | -0.29 | -22.08 | 10.10 | — |
| Weighted avg. shares (diluted) | — | 6.27M | 1.58M | — | 21.55M | 602,822 | 1.75M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.63M | $3.78M | $6.46M | $1.24M | $3.10M | $4.00M | $2.70M | $1.19M |
| Receivables | $31,000 | $16,000 | $21,000 | $15,000 | $3,000 | $3,000 | $9,000 | $18,000 |
| Current assets | $9.68M | $4.86M | $7.41M | $2.26M | $4.19M | $5.49M | $3.64M | $2.16M |
| PP&E, net | $62,000 | $73,000 | $79,000 | $77,000 | $81,000 | $100,000 | $114,000 | $151,000 |
| Total assets | $35.21M | $40.21M | $45.42M | $38.81M | $38.07M | $43.89M | $52.82M | $30.66M |
| Current liabilities | $23.80M | $4.09M | $3.66M | $14.84M | $10.46M | $10.51M | $9.78M | $35.45M |
| Total liabilities | $25.08M | $20.91M | $20.43M | $16.51M | $12.28M | $12.47M | $11.89M | $37.69M |
| Shareholders' equity | $27.45M | $35.05M | $39.52M | $33.97M | $32.52M | $37.53M | $44.99M | -$2.50M |
| Shares outstanding | 6.95M | 6.27M | 6.27M | 927,934 | 23.05M | 20.14M | 16.77M | 373,300 |
| Cash flow statement | ||||||||
| Operating cash flow | $2.42M | -$2.66M | -$2.62M | -$1.55M | -$896,000 | -$1.18M | -$1.58M | $94,000 |
| Capital expenditure | $8,000 | $13,000 | $22,000 | $14,000 | $3,000 | $8,000 | $6,000 | $4,000 |
| Free cash flow | $2.41M | -$2.68M | -$2.64M | -$1.56M | -$899,000 | -$1.19M | -$1.59M | $90,000 |
| Investing cash flow | -$8,000 | -$13,000 | -$22,000 | -$14,000 | -$3,000 | -$8,000 | -$6,000 | -$4,000 |
| Financing cash flow | $2.74M | $0 | $7.56M | $0 | -$2,000 | $2.49M | $3.10M | $330,000 |
| Depreciation & amortization | $19,000 | $19,000 | $20,000 | $18,000 | $22,000 | $22,000 | $43,000 | $69,000 |
| Stock-based compensation | $967,000 | $917,000 | $182,000 | $232,000 | $383,000 | $162,000 | $930,000 | $733,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.